Clinical TrialID 385
Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua
NCT03990272
Allergic Rhinitis
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Herb: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 385
- Evidence Id
- 385
- Core Evidence Id
- 385
- Source Clinical Trial Id
- 371
- Herb2 Clinical Trial Id
- HBCT000371
- Nct Id
- NCT03990272
- Title
- Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua
- Status
- Completed
- Phase
- Phase 3
- Study Result
- No
- Study Condition
- Allergic Rhinitis
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: AIT drops|DRUG: placebo drops
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult
- Enrollment
- 702
- Outcome Measure
- daily combined scores of medication and rhinoconjunctivitis symptoms (CSMRS), the daily combined scores of medication and rhinoconjunctivitis symptoms (CSMRS) (ranging from 0 to 6); which was calculated as the combined score of daily average scores of 6 rhinoconjunctivitis symptoms (rhinorrhea, nasal congestion, nasal itching, sneezing, ocular pruritus, and watery eyes) and the daily rescue medication score, at the peak pollen season(The start was defined as the first of 3 consecutive days with a pollen count of 50 pollen/m3 or greater each day. The end was defined as the last occurrence of 3 consecutive days with ≥50 pollen/m3 each day)
- Sponsor Collaborator
- Beijing Tongren Hospital|Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
- Funded By
- OTHER
- Location
- Beijing Shijitan Hospital, Beijing, China|Beijing Tongren Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|West China Hospital, Sichuan University, Chendu, China|Qingdao Municipal Hospital, Qingdao, China|No. 202 Hospital of PLA （General Hospital of Northern Theater Command ）, Shenyang, China|First Hospital of Shanxi Medical University, Taiyuan, China|Second Hospital of Shanxi Medical University, Taiyuan, China|Tianjin Medical University General Hospital, Tianjin, China|Shaanxi Provincial People's Hospital, Xi'an, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|General Hospital of Ningxia Medical University, Yinchuan, China|The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China
- Other Id
- TR-SLIT-AA-MC
- Start Date
- 2017-03-20
- Primary Completion Date
- 2017-10-22
- Completion Date
- 2017-10-30
- First Posted
- 2019-06-18
- Results First Posted
- Last Update Posted
- 2020-07-16
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT03990272
- Title Cn
- Title En
- Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua
- Bilingual Status
- semi_complete